New therapies targeting molecular pathways involved in ccRCC pathogenesis, such as agents targeting downstream genes of the VHL/HIF pathway -tyrosine kinase and mTOR inhibitors, have also shown encouraging effects. Here, MTOR is linked to nonpapillary renal cell carcinoma.